Zeltiq Aesthetics Inc  

(Public, NASDAQ:ZLTQ)   Watch this stock  
Find more results for Zeltiq Aesthetics Inc�
21.01
+0.04 (0.19%)
Aug 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 20.70 - 21.23
52 week 7.76 - 24.79
Open 21.00
Vol / Avg. 325,782.00/714,404.00
Mkt cap 788.41M
P/E     -
Div/yield     -
EPS -0.35
Shares 37.53M
Beta     -
Inst. own 98%
Oct 28, 2014
Q3 2014 ZELTIQ Aesthetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 18, 2014
ZELTIQ Aesthetics Inc Investor Day - 10:00AM EDT - Add to calendar
Sep 18, 2014
ZELTIQ Aesthetics Inc at Maxim Group Aesthetics Dinner Add to calendar
Aug 13, 2014
ZELTIQ Aesthetics Inc at Canaccord Genuity Growth Conference
Jul 29, 2014
Q2 2014 ZELTIQ Aesthetics Inc Earnings Call
Jul 29, 2014
Q2 2014 ZELTIQ Aesthetics Inc Earnings Release
Jun 11, 2014
ZELTIQ Aesthetics Inc at Goldman Sachs Healthcare Conference
Jun 10, 2014
ZELTIQ Aesthetics Inc at William Blair & Company LLC Growth Stock Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 5.88% -17.29%
Operating margin 5.88% -17.33%
EBITD margin - -15.78%
Return on average assets 13.19% -21.65%
Return on average equity 19.06% -28.57%
Employees 297 -
CDP Score - -

Address

Suite 100, 4698 Willow Road
PLEASANTON, CA 94588
United States - Map
+1-925-4742500 (Phone)
+1-925-4742599 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Zeltiq Aesthetics, Inc. operates as a medical device development company. It engages in the design, development, and commercialization of non-invasive procedures for the reduction of unwanted fat tissue. It develops Cryolipolysis, a technology that enables the reduction of fat tissue near nerves, muscle, and bones. The Company develops a non-invasive technology for aesthetic applications and plastic surgery. Its product is used as a skin cooling device to minimize pain and thermal injury during laser and dermatological treatments.

Officers and directors

Mark J. Foley President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Patrick Williams Chief Financial Officer, Senior Vice President
Age: 41
Bio & Compensation  - Reuters
Sergio Garcia-Rodriguez Senior Vice President, General Counsel and Corporate Secretary
Age: 52
Bio & Compensation  - Reuters
Keith Sullivan Senior Vice President of Worldwide Sales
Age: 56
Bio & Compensation  - Reuters
Len DeBenedictis Chief Technology Officer
Age: 73
Bio & Compensation  - Reuters
Carl Lamm Vice President of Operations
Age: 52
Bio & Compensation  - Reuters
Mary M. Fisher Director
Age: 52
Bio & Compensation  - Reuters
D. Keith Grossman Director
Age: 54
Bio & Compensation  - Reuters
Jean M. George Independent Director
Age: 56
Bio & Compensation  - Reuters
Kevin C. O'Boyle CPA Independent Director
Age: 58
Bio & Compensation  - Reuters